The SURMOUNT Trials: Tirzepatide's Weight Management Evidence
TRIAL-000002
Part of the DietApp.com GLP-1 Trial Database, a comprehensive, regularly reviewed resource.
What It Is
SURMOUNT is the clinical trial program that established tirzepatide's effectiveness for chronic weight management. SURMOUNT-1, published in NEJM in 2022, is the pivotal trial in the series and formed the primary basis for Zepbound's FDA approval.
Key Results
SURMOUNT-1 showed average weight loss of up to 20.9% of body weight at the highest studied dose over 72 weeks, a result researchers have described as the strongest single outcome in obesity pharmacotherapy to date at the time of publication. Later, SURMOUNT-5 became the first direct head-to-head trial comparing tirzepatide against semaglutide, finding tirzepatide produced significantly greater weight loss, 20.2% versus 13.7% at 72 weeks.
Side Effects Observed
Gastrointestinal effects, primarily mild to moderate nausea, were the dominant side effects across the SURMOUNT trials, consistent with what's seen across the GLP-1 and dual-agonist medication class generally.
A Real-World Perception Gap
A survey of 122 physicians found their estimated average patient weight loss (9.22%) was notably lower than what STEP and SURMOUNT trials actually reported (14.9% and 18.5% respectively), and physicians also underestimated trial-reported side effect rates. This is worth knowing, real-world outcomes and even provider expectations can diverge from published trial averages in either direction, which is part of why individual results genuinely vary.
References
- Jastreboff AM et al., SURMOUNT-1 Trial, NEJM 2022
- Applied Clinical Trials Online: SURMOUNT-5 Head-to-Head Results
- PMC: Physician Perceptions of GLP-1 Safety and Efficacy
Related Resources
Related Articles
How SURMOUNT Compares to Semaglutide's Own Evidence
| Trial | Population | Real Weight Loss Result |
|---|---|---|
| SURMOUNT-1 | Obesity, no diabetes | Up to 20.9% |
| SURMOUNT-5 | Head-to-head vs. semaglutide | 20.2% vs. 13.7% |
| STEP (semaglutide, for comparison) | Obesity, no diabetes | Up to 14.9-18.5% |
See DietApp's STEP Trials page for semaglutide's own weight-management evidence, and DietApp's Semaglutide vs. Tirzepatide comparison for the full medication breakdown.
Frequently Asked Questions
Is SURMOUNT-5 a fair head-to-head comparison? Yes, it's a real, direct, randomized comparison, genuinely more informative than comparing separate trials with different populations.
Why do physicians underestimate real trial results? Real-world clinical experience, incomplete familiarity with the latest data, or caution in setting patient expectations may all play a role.
Does higher average weight loss mean tirzepatide is right for everyone? No, individual tolerability, side effects, and personal health factors genuinely matter in this decision, not average results alone.
Explore More
Explore the full GLP-1 Tracker knowledge base on DietApp.com
Get Started
Download DietApp.com to track your own progress alongside the evidence behind your treatment.
About DietApp.com
DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. The information on DietApp.com is intended for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.
Last medically reviewed and updated: July 11, 2026.
surmount-trials-tirzepatide